Kezar Life Sciences Stock Price, News & Analysis

Kezar Life Sciences, a clinical-stage biopharmaceutical company, announced the grant of nonqualified stock options to three employees to purchase a total of 33,000 shares at an exercise price of $5.43 per share, equivalent to the closing price on March 2, 2023. The options will vest over four years, with 25% vesting after the first year and the remainder vesting monthly. This grant is part of the company's 2022 Inducement Plan and aims to attract new talent. Kezar is known for its innovative treatments for immune-mediated and oncologic disorders, including its lead asset, Zetomipzomib, currently in Phase 2 trials.

Kezar Life Sciences, a clinical-stage biotechnology firm focused on immune-mediated and oncologic disorders, announced that Dr. Noreen Roth Henig will participate in a panel discussion on Autoimmune/Complement/Inflammation at the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 7, 2023, at 10:30 am ET. A live webcast will be available on the company's website, with an archived version accessible for 90 days post-event. Kezar is advancing novel therapies, such as Zetomipzomib for lupus nephritis and KZR-261 for solid tumors, highlighting its commitment to innovative treatments.

Kezar Life Sciences, a clinical-stage biotechnology firm, announced the grant of nonqualified stock options to five employees for the purchase of 131,000 shares at an exercise price of $7.10 per share. This price matches the closing value on February 3, 2023, the date of the grant. The stock options are part of an inducement award linked to employment and will vest over four years, with initial vesting occurring one year after the employee's start date. Kezar is advancing treatments for immune-mediated and oncologic disorders, including drug candidates like Zetomipzomib and KZR-261.

Kezar Life Sciences, a clinical-stage biotechnology company, announced the granting of nonqualified stock options to two employees for purchasing 65,000 shares at an exercise price of $6.84 per share, equivalent to the closing price on January 6, 2023. The options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. This grant is part of Kezar’s 2022 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). Kezar is focused on developing breakthrough treatments for immune-mediated and oncologic disorders, including its lead asset, Zetomipzomib, used in clinical trials.

Kezar Life Sciences announces CEO John Fowler will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 2:15 pm PT in San Francisco, CA. The presentation will provide insights into the company's development of innovative treatments for immune-mediated and oncologic disorders. A webcast will be available on the company's website, with an archived version accessible for 90 days post-event. Kezar is focused on therapies like Zetomipzomib and KZR-261 to address chronic diseases and cancer.

Kezar Life Sciences (NASDAQ: KZR) announced the grant of nonqualified stock options totaling 65,500 shares to four employees, exercising at $7.07 per share, equal to the stock's closing price on December 5, 2022. These options are part of an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years. Kezar is focused on developing treatments for immune-mediated and oncologic disorders, with its lead candidate, Zetomipzomib, completing a Phase 2 trial for lupus nephritis and ongoing trials for KZR-261 targeting solid tumors.

Kezar Life Sciences, Inc. (KZR) reported positive results from the MISSION Phase 2 clinical trial of zetomipzomib for lupus nephritis (LN). Key findings include a significant increase in overall renal responses (ORR) from 64.7% to 88.2% by study’s end, with a median urine protein-to-creatinine ratio (UPCR) of 0.32. The treatment demonstrated a favorable safety profile, with no new safety signals and a reduction in corticosteroid use among participants. Results were presented at the ACR Convergence 2022, highlighting the potential of zetomipzomib for treating autoimmune diseases without immunosuppression.

Kezar Life Sciences, a clinical-stage biotechnology firm, announced the granting of a nonqualified stock option to one employee for 30,000 shares at an exercise price of $7.06 each. This decision aligns with Nasdaq's listing rules as an inducement for employment. The option will vest over four years, starting with 25% vested on the first anniversary of the employee's start date. Kezar is focused on developing innovative treatments for immune-mediated and oncologic disorders, including its lead candidate, Zetomipzomib, currently in clinical trials.

Kezar Life Sciences reported positive results from the MISSION Phase 2 trial for zetomipzomib in lupus nephritis, achieving an overall renal response in 64.7% of patients. The FDA granted IND clearance for this drug for treating autoimmune hepatitis. As of September 30, 2022, the company had $290.4 million in cash and equivalents, up from $208.4 million at the end of 2021. However, net loss for Q3 2022 was $17.8 million, compared to $14.5 million in Q3 2021, with increased R&D expenses.